{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:29Z","timestamp":1761871109740,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.clml.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:07:09Z","timestamp":1522454829000},"page":"380-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm"],"prefix":"10.1016","volume":"18","author":[{"given":"Steven M.","family":"Bair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Mato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.03.012_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1365-2141.2009.07727.x","article-title":"Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma","volume":"146","author":"Moskowitz","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.012_bib2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ajh.24792","article-title":"Outcomes in patients with relapsed\/refractory Hodgkin lymphoma (RR-HL) with progression after autologous stem cell transplantation in the current era of novel therapeutics","volume":"92","author":"Bair","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.03.012_bib3","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"K\u00fcppers","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2018.03.012_bib4","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2018.03.012_bib5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3324\/haematol.2015.132761","article-title":"The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints","volume":"101","author":"Vardhana","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.03.012_bib6","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"Review article The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib7","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ijc.24389","article-title":"Functional coexpression of interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin lymphoma","volume":"125","author":"Cattaruzza","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2018.03.012_bib8","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib9","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1002\/(SICI)1521-4141(199808)28:08<2424::AID-IMMU2424>3.0.CO;2-R","article-title":"Amplification of TCRbeta gene rearrangements from micromanipulated single cells: T cells rosetting around Hodgkin and Reed-Sternberg cells in Hodgkin disease are polyclonal","volume":"28","author":"Roers","year":"1998","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clml.2018.03.012_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V85.3.780.bloodjournal853780","article-title":"Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin disease cell lines","volume":"85","author":"Carbone","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib11","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1182\/blood-2008-01-134783","article-title":"Aberrant expression oaf the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3\u03b1","volume":"112","author":"Kreher","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/labinvest.2008.24","article-title":"The CD4+CD26- T-cell population in classical Hodgkin lymphoma displays a distinctive regulatory T-cell profile","volume":"88","author":"Ma","year":"2008","journal-title":"Lab Invest"},{"key":"10.1016\/j.clml.2018.03.012_bib13","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen\u2013specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib14","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","article-title":"Specific recruitment of CC chemokine receptor 4\u2013positive regulatory T Cells in Hodgkin lymphoma Fosters immune privilege","volume":"66","author":"Ishida","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.012_bib15","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2013-06-508044","article-title":"Defining characteristics of classical Hodgkin lymphoma microenvironment T-helper cells","volume":"122","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib16","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1038\/bcj.2016.26","article-title":"The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein\u2013Barr virus presence and location within the tumor","volume":"6","author":"Wu","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2018.03.012_bib17","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow-sorting and exome sequencing reveals the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"12","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib19","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.012_bib20","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib21","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib22","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1\u2013PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2567.2006.02354.x","article-title":"Deciphering CD30 ligand biology and its role in humoral immunity","volume":"118","author":"Kennedy","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.clml.2018.03.012_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1006\/smim.1998.0156","article-title":"CD30: expression and function in health and disease","volume":"10","author":"Horie","year":"1998","journal-title":"Semin Immunol"},{"key":"10.1016\/j.clml.2018.03.012_bib25","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","article-title":"Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin disease","volume":"68","author":"D\u00fcrkop","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.clml.2018.03.012_bib26","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1200\/JCO.1998.16.4.1532","article-title":"Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients","volume":"16","author":"Zinzani","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib27","first-page":"3736","article-title":"The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in\u00a0vitro and affects antitumor activity in models of Hodgkin disease","volume":"62","author":"Wahl","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.03.012_bib28","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/sj.leu.2403884","article-title":"Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin disease cells to conventional chemotherapeutics","volume":"19","author":"Cerveny","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.012_bib29","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood-2007-07-099317","article-title":"A\u00a0phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies","volume":"111","author":"Bartlett","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2141.2009.07740.x","article-title":"A\u00a0phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma","volume":"146","author":"Forero-Torres","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2018.03.012_bib31","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1200\/JCO.2006.07.8972","article-title":"Phase I\/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin lymphoma and anaplastic large-cell lymphoma","volume":"25","author":"Ansell","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib32","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib33","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.012_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.6004\/jnccn.2015.0076","article-title":"Biologic agents in the management of Hodgkin lymphoma","volume":"13","author":"Rashidi","year":"2015","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2018.03.012_bib35","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cncr.11511","article-title":"A\u00a0pilot study of rituximab in patients with recurrent, classic Hodgkin disease","volume":"98","author":"Younes","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.012_bib36","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2012-01-402792","article-title":"Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma","volume":"119","author":"Kasamon","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.03.012_bib38","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib39","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib40","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hon.2437_54","article-title":"Blockade of the PD-1 checkpoint with anti\u2013PD-L1 antibody avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (CHL) neoplasms and cardiovascular disease in long-term Hodgkin","volume":"35","author":"Chen","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib42","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/hon.2437_72","article-title":"Safety and efficacy of combination of brentuximab vedotin and nivolumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN cancer research group (E4412)","volume":"35","author":"Diefenbach","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/hon.2437_73","article-title":"Interim results from a phase 1\/2 study of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"35","author":"Herrera","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib44","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2018.03.012_bib45","first-page":"1","article-title":"Cancer therapy: clinical autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase i trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.03.012_bib46","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood.V126.23.583.583","article-title":"Nivolumab in patients (Pts) with relapsed or refractory classical Hodgkin lymphoma (R\/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039) (abstract)","volume":"126","author":"Ansell","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/hon.2437_124","article-title":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma after autologous transplant: full results after extended follow-up of the phase 2 Checkmate 205 trial","volume":"35","author":"Fanale","year":"2017","journal-title":"Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2018.03.012_bib48","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.V130.Suppl_1.651.651","article-title":"Nivolumab for newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL): results from the phase 2 Checkmate 205 study (abstract)","volume":"130","author":"Ramchandren","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib49","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1182\/blood.V128.22.1108.1108","article-title":"Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b Keynote-013 study (abstract)","volume":"128","author":"Armand","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib50","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood.V128.22.1107.1107","article-title":"Pembrolizumab in relapsed\/refractory classical Hodgkin lymphoma: primary end point analysis of the phase 2 Keynote-087 study (abstract)","volume":"128","author":"Moskowitz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib51","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/hon.2437_125","article-title":"Pembrolizumab monotherapy in patients with primary refractory classical Hodgkin lymphoma: subgroup analysis of the phase 2 Keynote-087 study","volume":"35","author":"Zinzani","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib52","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/(SICI)1096-9896(199710)183:2<182::AID-PATH918>3.0.CO;2-I","article-title":"In\u00a0vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas","volume":"183","author":"Xerri","year":"1997","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clml.2018.03.012_bib53","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/sj.leu.2404720","article-title":"CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease","volume":"21","author":"Fevery","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.03.012_bib54","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib55","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-05-500801","article-title":"Host programmed death ligand-1 is dominant over programmed death ligand-2 expression in regulating graft-versus-host disease lethality","volume":"122","author":"Saha","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib56","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.4049\/jimmunol.171.3.1272","article-title":"Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-dependent mechanism","volume":"171","author":"Blazar","year":"2003","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2018.03.012_bib57","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/j.bbmt.2016.12.161","article-title":"Nivolumab is effective in relapsed refractory Hodgkins lymphoma patient following mismatched allogeneic stem cell transplantation","volume":"23","author":"Browning","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2018.03.012_bib58","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40425-017-0211-z","article-title":"PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation","volume":"5","author":"Godfrey","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clml.2018.03.012_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-017-2181-9","article-title":"Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"106","author":"Onizuka","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2018.03.012_bib60","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/bmt.2015.266","article-title":"Nivolumab in a patient with refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Angenendt","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2018.03.012_bib61","first-page":"1","article-title":"Major clinical response to nivolumab in relapsed\/refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"1","author":"Yared","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2018.03.012_bib62","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/bmt.2016.346","article-title":"Tumor regression concomitant with steroid-refractory GvHD highlights the pitfalls of PD-1 blockade following allogeneic hematopoietic stem cell transplantation","volume":"52","author":"McDuffee","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2018.03.012_bib63","doi-asserted-by":"crossref","first-page":"13260","DOI":"10.18632\/oncotarget.7177","article-title":"Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective","volume":"7","author":"Villasboas","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2018.03.012_bib64","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bmt.2016.111","article-title":"Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin lymphoma","volume":"51","author":"Singh","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2018.03.012_bib65","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib66","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib67","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib68","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.03.012_bib69","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A\u00a0phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib70","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein-Barr virus-associated Hodgkin disease:\u00a0epidemiologic characteristics in international data","volume":"70","author":"Glaser","year":"1997","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2018.03.012_bib71","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00002371-200407000-00008","article-title":"The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease","volume":"27","author":"Bollard","year":"2004","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.clml.2018.03.012_bib72","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib73","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2018.03.012_bib74","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting epstein-barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib75","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cncr.20188","article-title":"Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease","volume":"100","author":"Lucas","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.03.012_bib76","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib77","first-page":"5920","article-title":"Circulating clonotypic B cells in classic Hodgkin lymphoma circulating clonotypic B cells in classic Hodgkin lymphoma","volume":"113","author":"Jones","year":"2009","journal-title":"Stem Cells"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2018.03.012_bib78","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1182\/blood.V130.Suppl_1.653.653","article-title":"Pilot study of non-viral, RNA-redirected autologous anti-CD19 chimeric antigen receptor modified T-cells in patients with refractory\/relapsed Hodgkin lymphoma (HL) (abstract)","volume":"130","author":"Svoboda","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib79","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.03.012_bib80","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2018.03.012_bib81","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1182\/blood.V130.Suppl_1.650.650","article-title":"Nivolumab treatment beyond investigator-assessed progression: outcomes in patients with relapsed\/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study","volume":"130","author":"Cohen","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.03.012_bib82","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2018.03.012_bib83","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018300879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:47Z","timestamp":1761870647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018300879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S2152265018300879"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}